ANO31905
/ Anova Innovation Limited
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 28, 2026
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
(clinicaltrials.gov)
- P1/2 | N=84 | Recruiting | Sponsor: Anova Innovation Limited | Initiation date: May 2026 ➔ Aug 2026 | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18
March 04, 2026
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
(clinicaltrials.gov)
- P1/2 | N=84 | Not yet recruiting | Sponsor: Anova Innovation Limited
New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18
1 to 2
Of
2
Go to page
1